Reevaluating corticosteroid premedication for rituximab: a retrospective cohort study

Leukemia & lymphoma/Leukemia and lymphoma 2026

View at publisher
Authors: Zynab El Shenawy, Mirjam Crul, Harmen Huls, Josephine M. I. Vos, Martine E.D. Chamuleau, Marie José Kersten, Marise R. Heerma van Voss
DOI: 10.1080/10428194.2026.2636704
Cited by: 0
References: 15

Abstract

Rituximab, a monoclonal antibody targeting CD20 on B-cells, is widely used in the treatment of B-cell malignancies and immune disorders [1,2]. However, infusion-related reactions (IRRs) are common,...

Fields of Study & Subjects

Drug-Induced Adverse Reactions Lymphoma Diagnosis and Treatment Pharmacovigilance and Adverse Drug Reactions

Publication details

Journal / source
Leukemia & lymphoma/Leukemia and lymphoma
Volume
67
Issue
7
Pages
1630–1633
Publication date
6 March 2026
Language
EN